These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 25717045)
1. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Capodanno D; Angiolillo DJ Circ Cardiovasc Interv; 2015 Mar; 8(3):e002301. PubMed ID: 25717045 [No Abstract] [Full Text] [Related]
2. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
3. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Bhatt DL Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708 [TBL] [Abstract][Full Text] [Related]
4. Antiplatelet effect of aspirin in patients with coronary artery disease. Grove EL Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204 [TBL] [Abstract][Full Text] [Related]
5. Personalized antiplatelet therapy for coronary artery disease patients: is this the future? Bonello L; Lemesle G; De Labriolle A; Barragan P; Camoin-Jau L; Paganelli F Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1525-32. PubMed ID: 19954314 [TBL] [Abstract][Full Text] [Related]
6. Dual antiplatelet therapy in coronary artery disease: a case-based approach. Raymond C; Menon V Cleve Clin J Med; 2009 Nov; 76(11):663-70. PubMed ID: 19884296 [TBL] [Abstract][Full Text] [Related]
7. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study. Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ; Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503 [TBL] [Abstract][Full Text] [Related]
8. Updates in antiplatelet agents used in cardiovascular diseases. Cheng JW J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473 [TBL] [Abstract][Full Text] [Related]
9. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
10. Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors. Chandrasekar S; Loomba R; Shah P; Arora R Am J Ther; 2013; 20(4):337-43. PubMed ID: 21519219 [TBL] [Abstract][Full Text] [Related]
11. Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors. Antonino MJ; Jeong YH; Tantry US; Bliden KP; Gurbel PA Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1011-22. PubMed ID: 23030291 [TBL] [Abstract][Full Text] [Related]
15. [Antiplatelet therapy for coronary artery disease: hot topics and prospects]. Han YL Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(31):2171-2. PubMed ID: 16321177 [No Abstract] [Full Text] [Related]
16. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Zeidner JF; Frishman WH; Lerner RG Cardiol Rev; 2008; 16(5):250-9. PubMed ID: 18708826 [TBL] [Abstract][Full Text] [Related]
17. [Platelet aggregation and antiplatelet agents in acute coronary syndromes]. Collet JP; Choussat R; Montalescot G Med Sci (Paris); 2004 Mar; 20(3):291-7. PubMed ID: 15067573 [TBL] [Abstract][Full Text] [Related]
18. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903 [TBL] [Abstract][Full Text] [Related]